CVRx | Barostim: Valuation, Funding & Investors
CVRx (Barostim) develops implantable neuromodulation medical devices that deliver baroreflex activation therapy (BAT) to treat cardiovascular conditions, principally heart failure and resistant hypertension. The company’s Barostim systems are designed to stimulate carotid baroreceptors to modulate autonomic (sympathetic/parasympathetic) activity, supporting improved cardiac function and symptom management within clinical care pathways for cardiovascular disease.
Leadership & Board
- Current Number of Employees
- 256
- Current LinkedIn Followers
- 21,924
Latest Estimated Valuation
- Total Amount Raised
- $50M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $50M
- Latest Funding Round
- Investment
Employee Trend
CVRx | Barostim had 256 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
CVRx | Barostim had 21,924 followers as of November 16, 2026. The number of followers increased by 75 (0.34%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 07, 2020 | Investment | $50.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Treo Ventures | Investment |
| Vensana Capital | Investment |
Similar Companies
A snapshot of private companies similar to CVRx | Barostim, helping you discover and navigate related company profiles.
Related News and Analysis









